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n the Fledgling
ield of Mechanical
irculatory Support*
ynne Warner Stevenson, MD, FACC,
regory Couper, MD
oston, Massachusetts
he First Flights
hen the Wright brothers launched the Kitty Hawk, no
ne ran alongside to test whether the machine would win
ver man for the first journey. The news was that the
achine could fly. Early experiences demonstrated the
uperiority of mechanical devices, including the device used
n this trial, to inotropic therapy for “bridging” transplant
andidates until donor hearts became available. The
EMATCH (Randomized Evaluation of Mechanical As-
istance for the Treatment of Congestive Heart Failure)
rial demonstrated that mechanical support could extend life
n patients who were not transplant candidates, with a
urvival of 52% at 1 year (1). Overall survival at 2 years was
9% at the final analysis and 38% during the last half of the
EMATCH trial (2).
See page 741
The INTrEPID (Investigation of Nontransplant-
ligible Patients Who Are Inotrope Dependent) trial (3) in
his issue of the Journal reports the next fledgling flight for
urable mechanical circulatory support. The nonrandom-
zed trial design reflects the ambivalence in the developing
eld; the dismal outcome of failed medical therapy pre-
ludes ethical randomization but is not well enough estab-
ished as a regulatory landmark for devices to pass. Even
ithout a comparable control group, this trial does effec-
ively close the question about this device in this population.
relative risk reduction of 50% is statistically significant,
ut the absolute mortality of 75% at 1 year is not an
cceptable outcome for a device intended for durable
upport.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.l
From the Cardiovascular Division and Division of Cardiac Surgery, Brigham and
omen’s Hospital, Boston, Massachusetts.ho Needs Wings?
ecent progress in mechanical circulatory support has been
eld back by inadequate identification of the patients who
re heading toward early death but are not yet dying.
inding appropriate patients for ventricular assist devices
VADs) should be somewhat easier than for cardiac trans-
lantation, for which patient selection involves not only the
everity and irreversibility of heart failure, but also the
amble of uncertain waiting times for donor hearts. For
oth of these decisions, however, the term “end-stage” has
een too imprecise. The INTERMACS (Interagency Reg-
stry of Mechanically Assisted Circulatory Support) study
as delineated clinical profiles of advanced heart failure
Table 1) that are becoming more objective as these data
ccumulate.
The REMATCH trial was designed to focus primarily
n ambulatory nontransplant candidates in profiles 4 and 5,
ut those actually consenting were more severely ill. Most
EMATCH patients were on inotropic infusions and in
rofiles 2 or 3 (1). By design, the patients in the INTrEPID
rial were also in profiles 2 and 3. These populations on
ntravenous inotropic therapy who received VADs in these
trials were equivalent in terms of the robust predictors of
dvanced heart failure outcome: average baseline sodium
34 mEq/l, creatinine 1.8 mg/dl, and pulmonary wedge
ressure 25 mm Hg (4). The mean age was 60 years in
he present INTrEPID trial compared with 67 in the
EMATCH trial, in which younger patients fared better.
ith devices, the 1-year survival for patients on baseline
notropic therapy was 49% from the REMATCH trial,
ompared with only 27% in the present trial.
The patients not receiving VADs in the present trial
ppeared more compromised than the VAD group, with
erum sodium of 128 mEq/l, creatinine of 2.1 mg/dl, and
ulmonary capillary wedge pressure of 29 mm Hg. It is not
urprising that these patients had a survival without devices
hat was worse than the comparable REMATCH patients,
1% versus 24%. Further differences between the device and
edical group in the present trial were 8% versus 28%
omen and 32% versus 56% prior bypass surgery. These
ifferences, as well as the financial reimbursement status,
ay also have influenced the selection for devices. The
edical therapy group in the INTrEPID trial is thus not a
omparable control for the device group.
Patients depending on intravenous inotropic therapy have
dismal outcome and should be offered devices if eligible.
owever, the broader target for current mechanical circu-
atory support is the ambulatory heart failure population
ho are not yet dependent on inotropic therapy or contin-
ed hospitalization but have very limited functional capacity
nd poor prognosis for survival (profiles 4 to 6) (Table 1). In
recent survey, the majority of ambulatory patients with
hronic symptomatic systolic heart failure indicated that
hey would consider an implanted device if they could walk
ess than a block or had 1 year to live (5). This has led to
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August 21, 2007:748–51 Editorial Commenthe consideration of “1 block or 1 year” as the signpost for
eferral for mechanical circulatory support.
Although a 1-block limitation is easy to identify, there
as not been enough focus on how to predict 1-year
ortality in advanced ambulatory heart failure. The last 20
ears of trials in mild to moderate heart failure have allowed
isk stratification before end-stage disease, as in the Toronto
odel and the Seattle Heart Failure Model (6,7). Such
odels need to better distinguish factors of heart disease
everity that would be addressed by mechanical support
rom comorbidities such as renal function that also increase
isk with device surgery. The impact of age is likely to
emain profound, as in the REMATCH trial; for patients
nder 60 years, the 1-year survivals were 74% with device
nd 33% without, whereas they were 47% and 15% for older
atients (1). More recent data at discharge from hospital-
zation for advanced heart failure led to the ESCAPE
Evaluation Study of Congestive Heart Failure and Pulmo-
ary Artery Catheterization Effectiveness) discharge risk
core (8), which includes systolic blood pressure, blood urea
itrogen, serum sodium, beta-blocker use, 6-min walk,
-type natriuretic peptide, recent need for resuscitation, and
oop diuretic dose. Prospective multicenter validation of risk
cores specifically for late-stage heart failure is crucial to
rovide benchmarks past which to advance the field. Once
quipoise has shifted toward devices, such benchmarks
hould replace the regulatory requirement for randomiza-
NTERMACS Profiles of Limitation at Time of Implant
Table 1 INTERMACS Profiles of Limitation at Time of Implant
Profile Description
1 Patient with life-threatening hypotension despite rapidly escala
inotropic support, critical organ hypoperfusion with increasi
levels and/or systemic acidosis. “Crash and burn”
2 Patient with declining function despite intravenous inotropic su
may be manifest by worsening renal function, nutritional de
inability to restore volume balance. “Sliding on inotropes”
3 Patient with stable blood pressure, organ function, nutrition, a
symptoms on continuous intravenous inotropic support, but
demonstrating repeated failure to wean owing to recurrent
symptomatic hypotension or renal dysfunction. “Dependent
4 Patient can be stabilized close to normal volume status but ex
frequent relapses into fluid retention, generally with high di
doses. Symptoms are recurrent rather than refractory. More
management strategies should be considered, which in som
reveal poor compliance. “Frequent flyer”
5 Patient is living predominantly within the house, performing ac
daily living and walking from room to room with some diffic
Patient is comfortable at rest without congestive symptoms
have underlying refractory elevated volume status, often wi
dysfunction. “Housebound”
6 Patient without evidence of fluid overload is comfortable at re
with activities of daily living and minor activities outside the
but fatigues after the first minutes of any meaningful activi
“Walking wounded”
7 A placeholder for future specification, patients without recent
fluid balance, living comfortably with meaningful activity lim
mild exertion.
odified from Stevenson (9).ion back to medical therapy that has failed. To remain valid, sowever, device benchmarks have to keep up with contempo-
ary therapy to reflect parallel downshifting risks (9).
It is assumed that patients portraying the more favorable
NTERMACS profiles will have better outcomes with
echanical support than the earlier experiences of sicker
atients. This seems reasonable, because a substantial mor-
ality occurs in the perioperative period. It is not yet certain,
owever, that patients with less imminent compromise will
erive greater net benefit with current devices. In the
EMATCH trial, the 1-year survival of 57% with mechan-
cal support for patients not initially on inotropic therapy
as higher than for the overall population, but the medical
urvival was also higher at 49% (4).
uture Flight Plans
he concept of mechanical circulatory devices to support
unctional survival has been validated during the past 40
ears of development and is further supported by the
NTrEPID trial (3). Before the conclusion of this trial, it
ecame clear from other experience that devices can no
onger be tested in this dying population in a simple
andomized trial design. However, the major questions
emain simple: How long and how well do the patients live?
The answer to how long is currently expressed not by
elative reductions of mortality, but in absolute survival with
given device. When survival without devices is negligible,
he main component of the equation of net benefit is the
Time Frame for Definitive Intervention
ate
Needed within hours
,
,
Needed within few days
ty”
Elective over a few weeks
ces
sive
es
Elective over weeks to months as long as treatment of episodes
restores stable baseline, including nutrition
s of
ay
l
Variable, depends upon nutrition, organ function, and activity
,
Variable, depends upon nutrition, organ function, and activity
le
o
Transplantation or circulatory support not currently indicatedting
ng lact
pport
pletion
nd
stabili
perien
uretic
inten
e cas
tivitie
ulty.
, but m
th rena
st and
home
ty.
unstab
ited turvival with devices. A case could be made, particularly
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Editorial Comment August 21, 2007:748–51ith hindsight, that the INTrEPID trial did not need a
ontrol group, because the major issue was outcome with
he device, not outcome without it. Had 75% of patients
urvived 1 year, the trial would have been positive. Had 50%
f patients survived 1 year, the device used would have been
ccepted as similar to the REMATCH device. Choices
etween the 2 would then be made by considering issues
uch as device durability and the risk of permanent neuro-
ogic events, both of which were high with the present
evice. However, the actual outcome of 25% survival at 1
ear would not generate sufficient enthusiasm for implan-
ation of this device even if it edged in front of the natural
istory of the disease.
For those patients who survive, the question is how well.
n parallel with the equation for survival benefit, when
uality of life is dismal the major component of quality
enefit is the quality of life with the device. New York Heart
ssociation functional class is too subjective to enlighten
ecision making. The heart failure questionnaires in the
resent study confirm that heart failure symptoms are
arkedly reduced, but different discomforts and limitations
rising from the device also need to be captured. Average
eak oxygen consumptions or 6-min walk distances, which
re routinely collected in the INTERMACS registry, en-
ance understanding of the physiology of the supported
irculation but do not facilitate individual decision making.
n example of the type of data important to patients and
heir physicians was provided by the REMATCH trial, in
hich 67% of survivors on devices experienced no limitation
n climbing a flight of stairs or walking 1 block, whereas
1% experienced some limitation bathing or dressing. The
istribution of these individual responses will become in-
reasingly important to guide timing of consideration for
echanical devices in the ambulatory population.
The pulsatile devices tested in the REMATCH and
NTrEPID trials have successfully launched the clinical era
or mechanical circulatory support. Experience is accumu-
ating with the nonpulsatile pumps, which currently offer
reater comfort and mobility with less circulatory pulsatility
nd reserve. The length of the flights for all has increased
rom a few months to a longer duration of durable support.
he field will hopefully grow to a stage where controlled
rials for advanced heart failure will have as their primary
nd points the functional and quality parameters, with
ssumed survival relegated to secondary end points of safety.
Whether devices are intended to bridge to transplant or
o provide permanent support at the time of insertion has
ecome less relevant, as many anticipated transplant candi-
ates now wait a year or longer on mechanical support,
uring which they may become ineligible. Patients initially
neligible may improve on support to resolve contraindica-
ions and become eligible. Initial transplant eligibility
hould no longer segregate the durable devices or the
ecipients, 40% of whom currently cannot be categorized
efinitively as either bridge or destination at the time of
mplant. When outcomes are consistently good beyond 2 tears, the devices will be seen not only as a bridge but as a
easible alternative to transplantation for the estimated
0,000 to 150,000 patients in the U.S. who could derive
mproved quality and length of life from cardiac transplan-
ation if there were more than 2,200 hearts annually.
Initial reports from the INTERMACS registry indicate
hat almost 80% of devices currently implanted are for
atients in INTERMACS profiles 1 and 2 (Drs. David
aftel and James Kirklin, personal communication, April 2,
007). Current outcomes already warrant extension beyond
hese inotrope-dependent patients to profiles 4, 5, and
ossibly 6 (10). When device and patient lifespan extend
eyond 3 years to 5 years, the field can lengthen to
ncompass patients whose disease is too early even to
ontemplate transplantation. Different devices than those
urrently used for complete circulatory support may even-
ually be used to prevent disease progression. At this
orizon, design may once again become feasible for a
raditional randomized control trial of device versus medical
herapy, which will also have evolved by that time.
Progress in the field of mechanical circulatory support
lso has been held back by nonuniform collection of data by
ndividual sites, companies, and countries. For a new tech-
ology with such promise for a disease with such prevalence,
ata consolidation must accelerate. A major advance is the
ormation of the INTERMACS registry, sponsored by the
.S. National Heart, Lung and Blood Institute (NHLBI).
he INTERMACS registry has brought together the Food
nd Drug Association, Joint Commission on Accreditation
f Healthcare Organizations, and Centers for Medicare and
edicaid Services in the U.S. to integrate and standardize
he regulatory, certification, and post-market approval as-
ects with the surgical, cardiology, and nursing staff of
xpert centers. One area in which such standardization is
ritical is in the uniform definitions of adverse events, such
s the neurologic events which occurred in most patients in
he present trial. The pilot for this registry was launched by
he International Society for Heart and Lung Transplanta-
ion (ISHLT), which is sponsoring the critical linking of the
.S. effort with the key international sites where many of
he advances have been pioneered in Europe, Japan, the
nited Kingdom, and Australia. After the launch of this
egistry in July 2006, virtually all of the major U.S. centers
re now enrolling patients, and the first formal analysis will
e available in late spring 2007.
There is widespread consensus, including from task forces
n mechanical circulatory devices from NHLBI and from
SHLT, that the next stage of acceleration will require the
ormation of a parallel advanced registry for patients with
dvanced heart failure. The INTrEPID trial demonstrates
ery clearly the dilemma posed when the target population
as not been well characterized. Heart failure has a worse
rognosis than most cancer, but heart failure lags far behind
ancer in the robust staging of patient profiles and progno-
is, as has been emphasized by Dr. Mariell Jessup. We need
o move beyond the retrospective construction of risk scores
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751JACC Vol. 50, No. 8, 2007 Stevenson and Couper
August 21, 2007:748–51 Editorial Commentrom mild to moderate heart failure populations and look
head to how to stratify contemporary patients in real time.
his registration of advanced heart failure is an essential
art of the future flight plan, not only to launch the
edgling field of mechanical circulatory support, but also to
rovide each patient with the best among all the therapies
ecoming available.
eprint requests and correspondence: Dr. Lynne Warner
tevenson, Cardiovascular Division, Brigham and Women’s Hos-
ital, 75 Francis Street, Boston, Massachusetts 02115.
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